AGENDA
Uniform Formulary Beneficiary Advisory Panel
30 March 2006

0700-0800	Sign-in	Naval Heritage Center Theater, 701 Pennsylvania Ave N.W, Washington, D.C. 20004
0800-0830	Welcome and Opening Remarks	MAJ Travis Watson
	Meeting Objectives	• Discuss recommendations of the DoD P&T Committee meeting, 14-16 February 2006, San Antonio, TX. • Discuss drugs in the therapeutic classes of: Overactive Bladder Drugs, Miscellaneous Antihypertensive Agents, and GABA analogs • Review Committee recommendations, make comments, and forward to the Director, TMA, for final decision to approve, disapprove, or modify the recommendations. • Entertain Private Citizen comments from 0830-0930. • Minutes of this meeting are being recorded and will be reduced to writing. All comments made here today are for the record and will be published.
0830-0930	Private Citizen Comments	• Up to twelve people who may have signed up to address the panel; will be given a maximum of 5 minutes each using the microphone. Time limit will be strictly enforced. • This time is set aside for public comment only and product endorsements, presentations of marketing strategies, or comments from industry are not appropriate. • Any comments or questions during other times will not be acknowledged.
0930-1000	Break	
1000-1100	Present Overactive Bladder Drug Class Review	TBD
	Panel Q & A BAP Discussion Vote / Comments	Ms. Sydney Hickey
1100-1200	Present Miscellaneous Antihypertensive Drug Class Review	TBD
	Panel Q & A BAP Discussion Vote / Comments Break	Ms. Sydney Hickey
1200-1300	Lunch	
1300-1430	Present outcomes of previous Uniform Formulary decisions	TBD
	Panel Q & A	Ms. Sydney Hickey

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

1430-1500	Break	
1500-1600	Present GABA analogs Drug Class Review	TBD
	Panel Q & A	Ms. Sydney Hickey
	BAP Discussion	
	Vote / Comments	
1600	Wrap-up/Adjourn	MAJ Travis Watson

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

0800-0830

1. **Convene**
The Department of Defense (DoD) Beneficiary Advisory Panel (BAP) will convene at 0800 hours on September 28, 2005 at the Naval Heritage Center Theater, 701 Pennsylvania Ave. N.W., Washington, D.C. 20004.

2. **Opening Remarks and welcome to panel members and audience**
   - Exits from the meeting room
   - Restroom facilities
   - Be courteous to your neighbor
   - Lunch options on your own

3. **Explanation of rules under which the BAP meeting will be conducted**
   - Only the Panel will actively participate in today's meeting
   - Only the Panel will address questions to any briefer
   - All audience comments and interaction will be confined to the 0830 – 0930 allotted time and then only to those designated and approved to address the panel as private citizens
   - Private citizen comments submitted in writing

4. **Beneficiary Advisory Panel members**
   John Class
   John Crum
   Deborah Fryar
   Marshall Hanson
   Sydney Hickey
   Rance Hutchings
   Lisa Le Gette
   Jeffrey Lenow
   Martha Miller
   Charles Partridge
   Jan Prasad
   Marissa Schlaifer
   Robert Washington

5. **Meeting objectives**

0830 – 0930

6. **Private Citizen comments**

0930 - 1000

7. **Break**

1000 – 1100

8. **Presentation of Overactive Bladder drug class review (TBD)**
   - Relative Clinical Effectiveness
   - Relative Cost Effectiveness
   - UF Implementation Plan

9. **Panel Q & A / Discussion of Overactive Bladder drug class (Ms. Sydney Hickey)**

10. **Vote / Comments**

1100 – 1200

11. **Presentation of Miscellaneous Antihypertensives drug class review (TBD)**
    - Relative Clinical Effectiveness
    - Relative Cost Effectiveness
    - UF Implementation Plan

12. **Panel Q & A / Discussion of Miscellaneous Antihypertensives (Ms. Sydney Hickey)**

13. **Vote / Comments**

1200 - 1300

14. **Lunch**

1300 – 1430

15. **Presentation of Outcomes of previous Uniform Formulary decisions (TBD)**

16. **Discussion of Outcomes presentation (Ms. Sydney Hickey)**

17. **No voting or comment required**

1430 – 1500

18. **Break**

1500 – 1600

19. **Presentation of GABA analogs drug class review (TBD)**
    - Relative Clinical Effectiveness
    - Relative Cost Effectiveness
    - UF Implementation Plan

20. **Panel Q & A / Discussion of GABA analogs (Ms. Sydney Hickey)**

21. **Vote / Comments**

1600

22. **Wrap-up/Adjournment**